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A B S T R A C T
Persistent Human Papillomavirus (HPV) infection is a prerequisite for cervical cancer development. Few studies
investigated clearance of high-risk HPV in low-and-middle-income countries. Our study investigated HPV
clearance and persistence over four years in women from North Tongu District, Ghana.
In 2010/2011, cervical swabs of 500 patients were collected and HPV genotyped (nested multiplex PCR) in
Accra, Ghana. In 2014, 104 women who previously tested positive for high-risk HPV and remained untreated
were re-tested for HPV. Cytobrush samples were genotyped (GP5+/6+ PCR & Luminex-MPG readout) in Berlin,
Germany. Positively tested patients underwent colposcopy and treatment if indicated.
Of 104 women, who tested high-risk HPV+ in 2010/2011, seven (6,7%; 95%CI: 2.7–13.4%) had ≥1 per-
sistent high-risk‐infection after ~4 years (mean age 39 years). Ninety-seven (93,3%; 95%CI: 86.6–97.3%) had
cleared the original infection, while 22 (21.2%; 95%CI: 13.8–30.3%) had acquired new high-risk infections with
other genotypes. Persistent types found were HPV 16, 18, 35, 39, 51, 52, 58, and 68. Among those patients, one
case of CIN2 (HPV 68) and one micro-invasive cervical cancer (HPV 16) were detected.
This longitudinal observational data suggest that single HPV screening rounds may lead to over-referral.
Including type-speciﬁc HPV re-testing or additional triage methods could help reduce follow-up rates.
1. Introduction
Cervical cancer is the fourth most common cancer in women,
causing approximately 266.000 registered deaths worldwide every
year. In many low-and-middle-income countries (LMICs) it is the
second most common cancer in women, representing a major burden
with the number of deaths accounting for 85% of the total cervical
cancer mortality rate globally [1]. Approximately 99.7% of cervical
cancers are caused by persistent infection with HPV genotypes, which
are classiﬁed as high risk [2]. However, HPV infections and resulting
lesions can be transient with, for example, only about 5% of cervical
intraepithelial lesion (CIN) grade II lesions progressing to invasion or
22% to carcinoma in situ [3]. It is postulated that probably less than
50% of women with CIN3 develop invasive cervical cancer within 30
years [4]. Nevertheless, it is known that persistent infection with high-
risk HPV increase the relative risk of developing high-grade cervical
intraepithelial lesions and invasive cancer [5,6]. Interestingly, the
prevalence of diﬀerent high-risk HPV types diﬀers between infection
and disease. In Western Africa HPV 16, 58, 18, 35 and 52 are the most
prevalent types in normal cytology, while in cervical cancer HPV 16,
18, 45, 59 and 35 are found most often [7]. One study from Ghana
shows HPV 18, 59, 45 and 16 as the most prevalent types in descending
order in conﬁrmed cervical cancer cases with HPV 18 being present in
47.4% of the cancer tissues [8]. Compared to the worldwide genotype
distribution within cervical cancer samples, for which the most
common HPV types were 16, 18, 31, 33, 35, 45, 52, and 58 [9], this
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order indicates regional diﬀerences. It has also been shown that the
carcinogenic potential for high-grade lesions diﬀers between the on-
cogenic HPV types. While the cumulative risk for the development of
CIN2+ after 14 years is 42.8 for HPV 16, it is only 8.1 for HPV 59 [10].
Persistence of diﬀerent HPV types is an important phenomenon for
the development of cervical cancer and its natural history. Elfgren et al.
showed in a small group that all women who continuously had geno-
type-speciﬁc high-risk HPV persistence developed CIN2+ lesions
within six years [11]. Despite this knowledge still relatively few studies
have reported persistence or clearance rates of HPV and the associated
risk of developing cervical cancer, especially in LMICs. In a population-
based cohort in Costa Rica, for example, a clearance rate of 55% of
carcinogenic HPV infections was observed after six months of follow-up
[12]. In Scotland, a clearance rate of 51.9% was seen after a period of
14 months [13]. Other studies from Costa Rica, Colombia, and Zim-
babwe found clearance rates of 67%, 77% and 73% within 12 months
[12,14,15]. These diﬀerent clearance rates highlight the need to further
investigate the natural history of HPV and cervical cancer in various
countries and settings.
This knowledge is of fundamental importance, since it greatly de-
termines future screening strategies and algorithms of HPV-based
screening for the prevention of cervical cancer, as is currently re-
commended by WHO [16]. We had an opportunity to compare geno-
type-speciﬁc HPV infections in a cohort of Ghanaian women. Our study
presents some rare data on clearance and persistence of HPV infections
found in a cohort of 104 women from the North Tongu District of Ghana
over the period of four years.
2. Materials and methods
2.1. Initial screening study
The recruitment strategy and patient ﬂow for this study is presented
in Fig. 1. As part of a cervical cancer screening project in 2010/2011,
3000 women attending the Battor Catholic Hospital in the North Tongu
District, Volta Region in Ghana, were screened for cervical cancer and
its precursor lesions. Women older than 15 years, with no history of
cervical cancer and not pregnant were recruited into the study. Women
who were unable to undergo speculum vaginal examination, including
virgins, those who had undergone hysterectomy or conisation and
women who were unable to give consent were excluded. Smear samples
were collected using an Aylesbury spatula and sent to the Cyto-
pathology Laboratory of the School of Allied Health Sciences, Uni-
versity of Ghana for cytological examination. Five hundred (500) of
these 3000 women were randomly selected for HPV genotyping using
nested multiplex PCR according to Sotlar et al. [17] at the Laboratory as
part of a PhD project undertaken by GB and supervised by EKW. The
following genotypes were tested for: 6/11, 16, 18, 31, 33, 35, 39, 42,
43, 44, 45, 51, 52, 56, 58, 59, 66, and 68. Ethical clearance for this
study was provided by the University of Ghana School of Allied Health
Sciences Ethics and Protocol Review Committee (Ref. No. SAHS ET/
AA/24A/2010). Signed/thumb-printed written/translated informed
consent was obtained from all women participating in the screening.
All the cytology reports were released to the Battor Hospital for
management and follow up. However, the HPV testing was started in
2011 and completed in 2013.
2.2. ACCESSING study – Follow-up
In 2013 collaboration between the Catholic Hospital Battor, Ghana
and the Charité University Hospital Berlin, Germany started with the
topic “Adequate Cervical cancer Capacity Building, Education and
Screening with new Scientiﬁc Instruments in Ghana”, namely the
ACCESSING study. This study was independent from the previous study
within a new collaboration but concentrating on the prevalence of HPV
and cervical cancer in the same geographical area. Ethical clearance for
this study was given by the Ghana Health Service Ethical Review
Committee (Ref. No. GHS-ERC: 05/05/13) in October 2013.
Recruitment for an initial pilot study started in March 2014 in order
to validate sample collection, logistics and diagnostic testing. For this
pilot study 150 women between the ages of 18–65 years with a previous
history of HPV infection or abnormal cytological result but currently
not pregnant were recruited at the gynecological clinic of the Catholic
Hospital Battor. Women who had remained untreated since 2011 and
fulﬁlled the criteria of this study were re-called and asked to participate
again for ﬁnal follow-up as part of this pilot. The participants were
recruited on a convenience approach. Potential diﬀerences in age and
HPV type positivity between women agreeing to and declining re-
cruitment in 2014 were assessed using chi-square test of independence.
Samples were collected for cytology and HPV genotype testing.
Cytological examination was done at the Department of Pathology,
University of Cape Coast, Ghana. HPV genotyping was done on
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positive/
69 HPV negative
Fig. 1. Flow chart of HPV screening studies in 2011 and 2014 presenting in-
clusion of 104 women by HPV test outcome and clinical diagnosis for persis-
tence analysis. Abbreviations: LSIL – low-grade squamous intraepithelial lesion;
CIN2 – cervical intraepithelial lesion grade 2.
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cytobrush samples by BSGP5+/6+ PCR followed by Luminex-MPG
read-out detecting the genotypes 6, 11, 16, 18, 26, 31, 33, 35, 39, 42,
43, 45, 51, 52, 53, 54, 56, 57, 58, 59, 66, 68a, 68b, 70, 72, 73, 82, and
90 at Charité Universitätsmedizin Berlin, Germany [18]. Diﬀerences in
age between women with cleared or persistent high-risk HPV infection
as well as newly infected women were tested using chi-square test.
Those who tested positive for high-risk HPV were recalled for colpo-
scopy and if indicated by colposcopy LEEP was performed. Based on the
histology results from the LEEP specimen additional treatment was
provided if needed. Every woman screened in 2014 ﬁlled out a ques-
tionnaire asking for general demographic data (e.g. age, education, and
income level per month) as well as speciﬁc risk factors such as age at
ﬁrst intercourse, number of sexual partners, etc.
For reasons of consistency the HPV high-risk classiﬁcation of WHO
was used, classifying the HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, and 59 as carcinogenic HPV genotypes. Additionally, we con-
sider HPV 66 and 68 as high-risk. The remaining types are deﬁned as
potentially carcinogenic or low-risk types [19]. It is important to note
that all carcinogenic high-risk types are detected with both assays,
however some low-risk types are not detected consistently with both
assays. The nested PCR according to Sotlar et al., as performed in Accra,
Ghana, included HPV 44, which was not tested with the BSGP5+/6+
PCR according to Schmitt et al. in Berlin, Germany, while HPV types 26,
53, 54, 57, 70, 72, 73, 82, and 90 were not tested by the nested PCR
method used in Accra. In the following analysis clearance and persis-
tence of low-risk types will therefore only refer to the HPV types 6, 11,
42, and 43 included in both assays.
3. Results
3.1. Characteristics of study participants
Attempt was made to contact all the women who tested high-risk
HPV positive in the Accra study in 2010/2011 and re-call them but only
104 out of the initial 210 women could be reached and agreed to
participate in the ACCESSING pilot study in 2014, and were re-screened
for HPV.
Comparing the age and HPV type positivity between the women
who agreed to participate and those who were not re-screened, we
observed only small diﬀerences. The median age of women re-screened
was 34 years in 2010/2011 and of those not re-screened 35 years. This
diﬀerence was not signiﬁcant (chi-square test; p-value= 0.336). When
tested to see if the initial positivity for the individual 14 high-risk HPV
types in 2010/2011 diﬀered between the two groups, we found that less
women re-screened were initially HPV52 positive compared to those
not re-screened (chi-square test; p-value= 0.001) and more of those re-
screened were initially positive for HPV68 (chi-square test; p-value=
0.028).
Among the women re-screened in 2014 almost one third (30.8%) of
the women had no formal education, 21.2% completed elementary
school, 47.1% completed secondary school and 1% continued with
post-secondary school education at the time of re-screening. More than
half (64.4%) of the women screened were married and the majority of
women (73.1%) had two to three sexual partners, as shown in Table 1.
The results from the questionnaire showed that more than two thirds of
the women (68.3%) did not use contraceptives.
3.2. Results initial screening study
Among the 104 high-risk HPV-positive women in the 2010/2011
study, 56 had single infections and 48 multiple infections and the mean
number of high-risk HPV types was 1.6. The most prevalent high-risk
HPV types were HPV 18 (26.0%), 58 (23.1%), 52 (22.1%), 68 (20.1%),
and 66 (14.4%). HPV 16 was detected in one sample (1.0%), the only
squamous cell carcinoma detected. HPV 43 was the most prevalent low-
risk type with 19.2%.
3.3. Results ACCESSING study
In 2014 no high-risk HPV infection was proven in 76.9% (80/104)
after approximately four years of follow up, with 73.1% (76/104) being
completely HPV negative while 3.8% (4/104) were positive for low-risk
HPV (6, 11, 42, or 43) only. Twenty-four (23.1%) women were high-
risk HPV positive. Altogether, 45 high-risk HPV infections and ﬁve low-
risk infections were found. Of the 24 high-risk positive women, 13 had
Table 1
Sociodemographic and behavioral characteristics of women included in HPV












Junior High School 35 33.65
Secondary 14 13.46
Post Secondary 1 0.96
Income level per month
<100 GH¢ 65 62.50
100–250 GH¢ 16 15.38
251–500 GH¢ 4 3.85
>500 GH¢ 2 1.92
missing data 17 16.35
Occupation
Farmer/Trader 70 67.31





Other (Baker, Caterer, Student, etc.) 10 9.62
missing data 5 4.81
Marital status
Single 6 5.77
Have a steady partner 9 8.65














missing data 1 0.96















Abbreviations: GH¢ - Ghana Cedi (local currency); N/A - no answer.
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single and 11 multiple infections with a mean number of 1.9 high-risk
HPV types (Range: 1–5). The most prevalent high-risk HPV genotypes
found were HPV 16 and 52 (8.7% each), 39 (4.8%) and 45 and 51
(3.8% each) among the 104 women. HPV 18 was diagnosed in none of
the samples. HPV 70 was the most prevalent low-risk type found in
4.8% (5/104) of the patients. This low-risk type had not been tested for
in the 2011 study. HPV 43 was found in only one of the patients.
3.4. Longitudinal comparison
Comparing the HPV genotyping results from 2010/2011 with the
results from 2014, 6.7% (7/104; 95% CI: 2.7–13.4%) women had ≥1
persistent high-risk HPV type (Table 2). None of the low-risk HPV types
persisted. Persistent HPV types found were HPV 16, 35, 39, 51, 52 and
68. HPV 52 persisted in three women, while the other HPV types were
found persistent in only one woman, respectively. One woman had two
persistent HPV types (HPV 51 and 52). Based on the comparison of
type-speciﬁc infections, the clearance rate found within four years was
93.3% (97/104; 95% CI: 86.6–97.3%) and rate of reinfection with a
new high-risk HPV type was 21.2% (22/104; 95% CI: 13.8–30.3%).
Clearance rates of HPV remained high throughout all age groups.
Proportions of women with reinfection with other high-risk HPV types
was 8.0% and 20.0% in the age groups 20–29 and 30–39 years, while it
was more than double in relative terms (30.8% and 33.3%) in the age
groups 40–49 and 50–59 years (Table 3). Most persistent cases could be
seen in the younger age groups (20–29 years with 2/7 cases and 30–39
years with 3/7 cases) compared to the remaining two cases across the
older age groups (40–49 years with 1/7 cases and 50–59 years with 1/7
cases).
When testing the association between persistence, clearance, and
reinfection rates across the diﬀerent age groups with chi-square test no
signiﬁcant association was seen.
3.5. Clinical outcome
Women testing positive for high-risk HPV in 2014 underwent col-
poscopic examination and a smear was taken for cytology. If a lesion
was suspected, women underwent LEEP for further histological con-
ﬁrmation and decision on further treatment was based on these results.
Out of the seven women who were positive for the same HPV type as in
2011, six women had normal cytology results. One cytology was un-
satisfactory and the woman was recalled for a repeat smear but was lost
to follow up. Her colposcopic examination had been inadequate due to
the lack of visibility of the transformation zone, with no visible changes.
She had persistent HPV 52 infection.
One of the six women with normal cytology had normal colposcopy
results, major changes were seen in three women, and two women were
suspected to have cervical cancer. Due to these abnormal ﬁndings
during colposcopy, four women underwent LEEP surgery, which
showed no lesion to be present in two women but revealed one case
each of CIN2 and microinvasive cervical cancer (Fig. 1). One of the two
women with suspected cervical cancer from colposcopy did not return
to the clinic for histological conﬁrmation and potential treatment. She
had persistent HPV 51 and 52 infections. The case of CIN2 was a
woman with persistent infection with HPV 68 and the case of micro-
invasive cancer was caused by persistent infection with HPV 16. The
other two women having HPV 35 or 52 persistent HPV infections had
no lesions. Unfortunately, two of these seven women were lost to follow
up despite several attempts to convince them for triage and treatment.
Out of the 17 women who were re-infected with high-risk HPV
genotypes 13 had normal cytology, one woman was diagnosed with
LSIL, for one woman the Pap-smear was unsatisfactory and two women
were lost to follow-up without cytology results. On colposcopic ex-
amination of the 15 triaged women 11 women were diagnosed as
normal, three women showed major colposcopic changes, of whom one
was cytologically conﬁrmed LSIL, and one woman was suspicious for
cancer. The woman suspicious of cancer had normal cytology results
Table 2
Prevalence in 2011 and 2014 and Persistence/Clearance/Reinfection of high-risk HPV by type among study participants (n= 104).
HPV Type Prevalence of high-risk HPV in 2011 Prevalence of high-risk HPV in 2014 Persistence Clearance Reinfection
n % n % n % n % n
HPV 16 1 1.0 9 8.7 1 100.0 0 0.0 8
HPV 18 27 26.0 0 0.0 0 0.0 27 100.0 0
HPV 31 7 6.7 2 1.9 0 0.0 7 100.0 2
HPV 33 7 6.7 0 0.0 0 0.0 7 100.0 0
HPV 35 11 10.6 2 1.9 1 9.1 10 90.9 1
HPV 39 6 5.8 5 4.8 1 16.7 5 83.3 4
HPV 45 1 1.0 4 3.8 0 0.0 1 100.0 4
HPV 51 13 12.5 4 3.8 1 7.7 12 92.3 3
HPV 52 23 22.1 9 8.7 3 13.0 20 87.0 6
HPV 56 8 7.7 1 1.0 0 0.0 8 100.0 1
HPV 58 24 23.1 1 1.0 0 0.0 24 100.0 1
HPV 59 1 1.0 3 2.9 0 0.0 1 100.0 3
HPV 66 15 14.4 2 1.9 0 0.0 15 100.0 2
HPV 68 21 20.2 3 2.9 1 4.8 20 95.2 2
All HPV 165 45 8/165 4.8 157/165 95.2 37
(95% CI: 2.1–9.3%) (95% CI: 90.7–97.9%)
In 104 women 104 24 7/104 6.7 97/104 93.3 21.2% (22/104)
(95% CI: 2.7–13.4%) (95% CI: 86.6–97.3%) (95% CI: 13.8–30.3%)
Abbreviation: CI - Conﬁdence interval.
Table 3
Persistence, Clearance, and Reinfection between 2011 and 2014 by age group
(n=104).
Age group Persistence Clearance Reinfection
n n % n % n %
20–29 25 2 8.0 23 92.0 2 8.0
30–39 30 3 10.0 27 90.0 6 20.0
40–49 26 1 3.8 25 96.2 8 30.8
50–59 15 1 6.7 14 93.3 5 33.3
60+ 6 0 0.0 6 100.0 1 16.7
Unknown 2 0 0.0 2 100.0 0 0.0
Total 104 7 6.7 97 93.3 22 21.2
95% CI 2.7–13.4% 86.6–97.3% 13.8–30.3%
chi-square test 1.03 1.03 4.67
p-value 0.795 0.795 0.197
Abbreviation: CI - Conﬁdence interval.
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and a LEEP biopsy specimen revealed a CIN2 lesion on histological
examination. No further histological conﬁrmation was obtained for any
of the other women.
4. Discussion
This comparative analysis of two independent HPV genotyping
projects in smears from the same group of women sampled years apart
was used to determine the persistence and frequency of resolution of
prevalent HPV infections.
The most remarkable result emerging from this study is that after an
exceptionally long follow-up period of four years, high-risk HPV in-
fection persisted in only 6.7% (95% CI: 2.7–13.4%) of the women.
Almost three quarters of the women had completely cleared their high-
risk HPV infection and were HPV-negative at the time of follow up,
without receiving any form of treatment in the intervening period. It is
important to note that a total of 21.2% (95% CI: 13.8–30.3%) had been
re-infected with new high-risk HPV types. Such infections become only
apparent as new and non-persistent by genotyping HPV assays and
could have been mistaken as persistent high-risk HPV infections.
Persistent infections would be classiﬁed with a higher risk of malignant
transformation compared to those with a type change or clearance [11].
The clearance and persistence rates found are concordant with other
studies having such a long follow-up period. In a study from Columbia
among women with a median age of 29 years a clearance rate of 93%
was found after ﬁve years of follow up [14]. Even at shorter follow-up
periods remarkably high clearance rates can be found. At six months for
example clearance of 55% and at 12 months of 67% is reported for
oncogenic HPV in a study population in Costa Rica [12]. In South Korea
77% of high-risk HPV cleared within 18 months [20]. The median time
to clearance reported by Giuliano et al. is 9.8 months for oncogenic
types and 4.3 month for non-oncogenic types [21]. Muñoz et al. report a
similar trend in which oncogenic types have longer time to clearance
compared to non-oncogenic types and especially HPV 16 infections
clear after signiﬁcantly longer time intervals compared to low-risk HPV
and other high-risk non α-9 types [6].
There was no evidence for an association between clearance or
persistence rates and age. This could be due to the low number of
women who were diagnosed with the same HPV type after four years.
There was also no association between reinfection and the diﬀerent age
groups. Several studies have shown though that women at younger age
and after initiation of sexual activity tend to have high prevalence rates
but that infections clear quickly, in contrast to women at older ages,
which tend to have lower prevalence rates, resulting rather from per-
sistent infections [22].
With the switch of many national cervical cancer screening pro-
grams to HPV-testing based screening these results may support the
available evidence on clearance that is needed to decide on the duration
between screening visits.
WHO recommends to initiate screening programs based on HPV
testing instead of cytology in countries that have no program in place
[16].
Interestingly, none of the low-risk HPV types detected in 2011
persisted. This is also consistent with ﬁndings from other studies. In
Columbia, low-risk HPV types were found to have a lower persistence
rate compared to HPV 16 [14]. In a study from Zimbabwe persistence of
low-risk HPV types was 21.9% over a median period of 21 months,
which was signiﬁcantly lower compared to high-risk HPV types with
37.3% persistence [15].
Diﬀerent oncogenic HPV types have diﬀerent duration until clear-
ance and diﬀerent carcinogenic potential. Within our study population
we found the HPV types 16, 35, 39, 51, 52 and 68 to be persistent.
Among these HPV 16 and 68 caused conﬁrmed invasive cervical cancer
and CIN2 within the follow-up period, respectively. The woman found
with persistent HPV 16 infection was diagnosed with invasive cervical
cancer after an abnormal colposcopic ﬁnding and LEEP biopsy. It was
remarkable that she presented with a normal cytological result of NILM
“Negative for Intraepithelial Lesion and Malignancy” in 2014. The
histologically examined LEEP specimen indicated micro-invasive cer-
vical cancer, upon which a radical hysterectomy was performed.
In comparison, among the 17 women who were found newly in-
fected with high-risk HPV during the second testing round in 2014 only
one case of CIN2 was detected. Cytology detected one woman with
LSIL, from whom no biopsy could be taken.
While HPV 16 clearly is the main driver of cervical cancer and can
be found in most cases of cervical cancer worldwide [9], HPV 68 is not
very common in high-grade lesions [23]. Only in South Africa has HPV
68 been found to be among the “Top 10″ cervical cancer-causing HPV
types [7].
HPV 16 has been reported in the literature as the HPV type that
persists signiﬁcantly longer or in other words has lower clearance rates
compared to other HPV types. Bulkman et al. showed in a population-
based cervical screening cohort with 44.102 women that the type-
speciﬁc clearance rates of high-risk HPV diﬀer with HPV 16 and HPV 31
having signiﬁcantly lower clearance rates in women with normal cy-
tology results at baseline [24]. Moreover, HPV 16 is also the type with
the highest detection rate (12%) of CIN3+ within 18 months after
normal cytology at baseline [24].
This has also been presented in other studies. Wheeler et al. for
example showed that the 2-year cumulative risk of developing CIN3+
for women with equivocal or mild cervical cytological abnormalities is
diﬀerent depending on the HPV type present. For HPV 16 the risk was
39.1%, while for the other high-risk types the cumulative risk was only
7.9% [25]. This trend can also be seen at 10 years in a study conducted
by Khan et al. There, the cumulative incidence rate observed for CIN3+
among women with normal cytology at baseline was 20.7% for
HPV 16+, and 17.7% for HPV 18+ women. In contrast, it was 1.5% for
women who were non-HPV 16/18 high-risk positive [26]. A recent
study conducted by Smelov et al. reported on the cumulative risk for
CIN3+ from a 14-year follow-up study. The risk when HPV 16-positive
at baseline was 34.5 as compared to 20.7 when positive for any high-
risk type or 0.9 when HPV-negative [10]. Additionally, the analysis
mentioned above by Elfgren et al. showed that all 40 women followed
with HPV genotyping and persistent identical HPV type infection de-
veloped CIN2+ lesions within six years of persistence irrespective of
the type the women remained positive for [11].
Based on the knowledge gained about type-speciﬁc clearance rates
and risks for the development of CIN3+, repeat genotype testing within
the regular screening algorithm for cervical cancer prevention should
be considered and could greatly inﬂuence follow-up of HPV positive
women [27]. This is of particular importance, considering that cy-
tology-based screening algorithms have been shown to be inadequate in
many settings for reasons such as limited sensitivity, limited human and
ﬁnancial resources, and poorly developed healthcare services and ac-
cess to primary healthcare facilities [28]. Therefore, HPV testing is
recommended for cervical cancer screening in low-resource settings by
WHO since 2013 [16]. It is important though to consider the high
sensitivity of HPV testing and the low positive predictive value for
detection of cervical cancer of the HPV tests currently available for
screening. It helps in ﬁnding more CIN2+ cases, compared to cytology,
that are in need for treatment but at the same time may lead to a very
high referral rate of HPV positive patients for follow-up and highlights
the need for further triage strategies of HPV positive patients [29,30].
High referral rates will result in a burden for the already low-staﬀed
health care systems in LMICs. While persistence of high-risk HPV with
the identical type according to Elfgren et al. should be recognized as a
leading risk factor for the development of cervical lesions and if pos-
sible included in the screening algorithms [11], they also highlight the
diﬃculties in managing follow-up for persistence patients.
Although the risk of developing lesions from persistent HPV infec-
tions is increased, we found ﬁve patients who had not developed any
lesions, even after the extended time of persistent infection of four
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years. Castle et al. have described this phenomenon in a group of pa-
tients from Guanacaste, Costa Rica, who had persistent high-risk HPV
infection without developing lesions, even after a mean follow-up
period of 6.5 years. He suggests that an unmeasured susceptibility
factor may hinder women from clearing their HPV infections but not
necessarily result in the development of cervical lesions [31].
Bearing in mind the fact that in 2014 23% of the women were high-
risk HPV positive, yet direct comparison of the HPV types revealed
persistent infection in only 6.7% of the women, the importance of HPV
genotyping tests is highlighted compared to group tests for high-risk
HPV types. Especially when using persistent HPV infection as the basis
for clinical follow-up, additional 16.3% (17/104) of the women would
have been classiﬁed high-risk HPV persistently positive with a generic
group test while they actually had cleared the original HPV types and
were re-infected with a new high-risk type. Khan et al. suggested at
least HPV 16 and 18 genotyping to increase the positive predictive
value of HPV testing and potentially even create screening algorithms
that immediately refer HPV 16/18 positive patients for colposcopy
[26]. This has also been evaluated in the ATHENA study and conﬁrmed
the eﬀectiveness of direct referral of HPV 16 or 18 positive women with
NILM cytology for colposcopy as it is currently recommended in the
2006 American Society of Colposcopy and Cervical Pathology guide-
lines [32]. Genotyping was also shown to provide high sensitivity and
speciﬁcity for the possible recurrence of disease after CIN treatment, as
a ‘test of cure’ [27,33]. Yet most of the currently available results are
focused on partial genotyping only. Therefore, larger prospective co-
hort studies investigating the type-speciﬁc clearance, especially of non-
HPV 16/18 types, such as HPV 31, 33 and 45 are needed.
Within our study we did not analyse potential risk factors for per-
sistence of infection due to the small study group. However, in the
literature, aspects such as age, cigarette smoking, parity, and oral
contraceptive usage are described as characteristics associated with
persistence of HPV infection [14] and could be included into risk as-
sessment for HPV genotype persistence. We did not ﬁnd an association
between persistence and age, most likely due to the small study group
with persistent infection, as mentioned above.
Despite the fact that this study reveals some important insight into
the long-term persistence of high-risk HPV infected women with a time
period of four years before follow-up, there are limitations due to the
opportunistic character of this analysis. The study follow-up and long-
itudinal analysis was not intended from the beginning. The greatest
limitation is that HPV genotyping was performed with two diﬀerent
HPV genotyping tests in 2011 and 2014. This may lead to mis-
classiﬁcation of persistent infections due to the diﬀerent targets of the
tests (E6 and E7 vs L1) as well as the potentially diﬀerent sensitivities
and speciﬁcities and thus the results need to be interpreted with cau-
tion. HPV 18 was seen very frequently during the screening round in
2010/2011, yet no case of HPV 18 was seen in 2014 anymore. Beside
from the clearance of HPV 18, this could be due to diﬀerent sensitivities
of the tests for HPV 18. Furthermore, the genotyping tests were also
performed in diﬀerent laboratories (Accra, Ghana and Berlin, Germany)
resulting further in potential inter-laboratory diﬀerences, which limits
the reliable comparison of HPV types found and, therefore, the classi-
ﬁcation of persistent infection.
HPV testing was performed only at two time points within the
follow-up period despite the recommendations proposed by Muñoz and
Koshiol [5,6]. Especially Muñoz suggested that only incident infections
lasting longer than the median duration of infection should be con-
sidered persistent. A common problem is though that this re-
commendation is not yet widely used. As a consequence, this study
cannot provide additional information on the time to clearance except
from this point prevalence.
In addition, the quality of cytology performed on the samples from
2014 may not be perfectly adequate. At least one conﬁrmed case of
invasive cervical cancer was classiﬁed with normal cytological ﬁndings
and two additional histologically conﬁrmed cases of CIN2 were missed.
Furthermore, cytology and colposcopy was only performed on women
tested high-risk HPV positive in 2014 and not on those women tested
HPV negative.
5. Conclusion
The main ﬁnding that only 6.7% of high-risk HPV types persisted
after four years is of signiﬁcant importance and should be considered
for future prospective studies evaluating potential screening algo-
rithms. Especially at a time of paradigm shift from cytology to HPV
testing for the prevention of cervical cancer, further research on the
signiﬁcance and feasibility of genotyping for screening is urgently
needed. This longitudinal observational data suggest that single HPV
screening rounds may lead to over-referral. Including type-speciﬁc HPV
re-testing or additional triage methods could help reduce follow-up
rates. Despite the limitations mentioned but also due to the highly in-
teresting and important results seen in this pilot trial the performance
of further prospective long-term cohort studies investigating clearance
and persistence of individual HPV genotypes especially in high pre-
valence populations in LMIC is warranted.
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